Valerio Therapeutics Société anonyme (0NWK.L)
LSE · EUR
€0.392 (-1.63%) as of
Key statistics
- EPS (TTM)
- -0.0700
- 52-week range
- 0.1229 – 0.3935
- Beta
- 2.13
- Revenue (TTM)
- 5.55M
- Profit margin
- -127.07%
- Volume
- 1.52k
About Valerio Therapeutics Société anonyme
Valerio Therapeutics Société anonyme, a clinical-stage biotechnology company, develops technology platforms dedicated to the targeted delivery of therapies. The company develops PlatON, a proprietary chemical platform for DNA decoy therapies, which generates new compounds and broadens its product portfolio; DecoyTAC, a mechanism of action of DNA decoy therapies coupled with targeted protein degradation; and V-body platform, a bispecific T-cell engagers, antibody drug conjugates, and chimeric antigen receptors. The company was formerly known as Onxeo SA and changed its name to Valerio Therapeutics Société anonyme in June 2023. Valerio Therapeutics Société anonyme was incorporated in 1997 and is headquartered in Paris, France.
- Headquarters
- Paris, France
- Employees
- 41
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.